September 2022 layoffs.

Quote






anonymous said:
Has anyone noticed how quiet things are? And how many manager don't know much about company direction? This does not look good.
Click to expand...

Yep it is looking like something is coming. There is no way we can have this many people selling Austedo. This tells us they do not see Ajovy sales improving and who knows what is going on with Uzedy. Teva cant get rid of the NP sales force becasue they are the ones that have been constantly calling on almost all the writers.

Makes you think, will they keep NP mostly in tact? gutting NS since NH has Uzedy possibly coming out soon? are they giving up on Uzedy? Or will it be a restructuring of NP/NS with a larger sales division but smaller territories? No matter how you look at it, too many people selling Austedo. The company knows it. Something is coming. No idea what.
 






OP here...cuts are coming and they are bigger than any of us thought. Austedo is underperforming, after a 153m Q1, its trending to a similar number with essentially twice the voice. Ajovy is almost like a commodity drug...the discounts given by all the injectables make this a losing proposition. No footprints yet but looks like 50 LTC reps and ~240 person sales force carrying both Austedo and Ajovy. Weightings will depend of number of neuros etc. Uzedy delay was the worst case scenario with all these other schizo meds coming out this year. Most Uzedy new hires and sales team will be severed and it may be before September like we thought it was going to be originally.
 






Quit with all this downsizing and layoff crap. We are interviewing and filling open territories right now ahead of the Q-3 Javelin Call Plan process. Why in the world would Teva spend the money for recruiting and onboarding, not to mention the cost of keeping all these vacant territories backfilled if there was an eminent layoff coming in 3 months. Do you not know that the backfilling of field sales reps and the hiring process is one of the highest costs to the organization's bottom line Yes the Uzedy side is probably done, but NP and NS will be kept whole with Austedo and Ajovy. Go look at the Teva Careers site and see all the territories currently being recruited for.
 






anonymous said:
Quit with all this downsizing and layoff crap. We are interviewing and filling open territories right now ahead of the Q-3 Javelin Call Plan process. Why in the world would Teva spend the money for recruiting and onboarding, not to mention the cost of keeping all these vacant territories backfilled if there was an eminent layoff coming in 3 months. Do you not know that the backfilling of field sales reps and the hiring process is one of the highest costs to the organization's bottom line Yes the Uzedy side is probably done, but NP and NS will be kept whole with Austedo and Ajovy. Go look at the Teva Careers site and see all the territories currently being recruited for.
Click to expand...

Reorg with many being let go is probably what will happen. Javelin is a program to find out where a company can trim its sales divisions. Teva is trying to find out how to downsize NS and NH while expanding NP to drive Austedo sales. I expect NS and Uzedy to be the most downsized because their markets are just so competitive and so many new drugs coming out. I think Migraine has 3 new drugs coming out over the next 4-6 months. That will cut into Ajovys already small profits. Uzedy has 6-8 new LAI drugs to compete with in an already competitive and crowded market. Teva's revenue stream is shrinking and they just cant keep this many sales people for a drug that is not approved and another that is about to be muscled out by competition. Austedo is the only drug that is growing for teva. I expect them to be looking for ways to expand that division a little.
 






Ajovy is a disappointment. With newer drugs coming out NS will see some downsizing. The drug is not growing fast enough and currently is 3rd or 4th compared to current products. With 3 more coming out with money to back them up. Ajovy is going to see profits shrink more over the next 6 months.

Uzedy was supposed to be the first of 6 new drugs in the class to come out over the next 6-8 months. Now it will be one of the last drugs to market in an already competitive and very crowded market. I do see Teva going full steam ahead with Uzedy early next year. I think the big thing with Uzedy was to get out of the gates quick and take market share. That will not happen now. Time will tell how this one does, but right now not a good start.

with the current economic situation and inflation I see teva downsizing in Oct 1 like they did last year after Javelin.
 










































Looks like the re-org is starting from the top with ‘temporary’ position changes
Anybody not think this will soon trickle down to sales layoffs?
And it has been one month since the meeting with the FDA and still no update on the resubmit
 






anonymous said:
Looks like the re-org is starting from the top with ‘temporary’ position changes
Anybody not think this will soon trickle down to sales layoffs?
And it has been one month since the meeting with the FDA and still no update on the resubmit
Click to expand...

Denial is a dangerous emotion. Above poster is more right than wrong. The drive for increased activity (programs, spend, samples, collaboration) is to distract us from focusing on the uncertainty. Very few ‘decisions’ are being made except the pressure for calls and activity. This isn’t leadership. We can do their job, they can’t do our job.
 






OP here...people are getting shuffled around at the top and some have "left" quietly to pursue other opportunities. If you can't see that these cuts are coming in September/October like I told you then you just can't be helped. Look at the headcount for Austedo alone. I will probably be let go as well but just trying to help you enlighten your search.
 






anonymous said:
OP here...people are getting shuffled around at the top and some have "left" quietly to pursue other opportunities. If you can't see that these cuts are coming in September/October like I told you then you just can't be helped. Look at the headcount for Austedo alone. I will probably be let go as well but just trying to help you enlighten your search.
Click to expand...

Teva has been forecasting austedo to be a billion dollar drug for years and have come up short both times. Teva has missed on quarterly reports 2 out of the last 3 quarters. Revenue has continually dropped every year since 2015. Teva had 153m with austedo in q1. A very slow start to hit a billion. This means austedo has to hit 283m each quarter to hit a billion. Let's not forget teva has 3 sales divisions now selling austedo. 1 does not have their own drug. Cutting into profits. The other struggling with ajovy and part time selling austedo. You have 2 sales divisions draining profits. Depending on uzedy approval, we will see if it is a massive layoff or restructuring. But it's obvious we will see something soon. I would not want to be in NS right now. Depending on approval, I would not want to be in NH either. I still do not think they figured out what they are doing with uzedy yet since all the higher ups are moving around or leaving. If auest is not above 283 in q2 sales, big changes will happen
 






anonymous said:
Quit with all this downsizing and layoff crap. We are interviewing and filling open territories right now ahead of the Q-3 Javelin Call Plan process. Why in the world would Teva spend the money for recruiting and onboarding, not to mention the cost of keeping all these vacant territories backfilled if there was an eminent layoff coming in 3 months. Do you not know that the backfilling of field sales reps and the hiring process is one of the highest costs to the organization's bottom line Yes the Uzedy side is probably done, but NP and NS will be kept whole with Austedo and Ajovy. Go look at the Teva Careers site and see all the territories currently being recruited for.
Click to expand...

This means nothing. If you've spent anytime in the industry companies were in process of hiring or onboardi g before the surprise email that you've got an emergency townhall today at 430pm. Happens all the time.
 


















anonymous said:
Something is not right at teva. A bloodbath is coming.
Click to expand...
Close to everything is not right at TEVA. 2019 was supposed to be the bottoming out of sales and then back to growth. The company is a shambles no R&D assets coming, new products and generics falling over and management obsessed with measuring everything but their own failures and incompetence. Anyone who can’t see the reckoning coming is wearing a blindfold.
 






Top Bottom
Back
Quote